Boston Scientific insider files Form 4: option grant and 50,000-share sale detailed

Rhea-AI Filing Summary

Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific (BSX), reported option activity and open-market sales on 10/01/2025. The filing shows a grant of a stock option to purchase 50,000 shares with an exercise price of $26.15; the option vests in four equal annual installments and the reported exercisable/expiration schedule lists an expiration of 12/01/2027. On the same date the reporting person sold 8,245 shares at a weighted average price of $98.9063 and 41,755 shares at a weighted average price of $98.3797, totaling 50,000 shares sold. The transactions were effected under a pre-established Rule 10b5-1 trading plan adopted 02/27/2025. The report disclaims beneficial ownership of 5,234 shares held by the reporting person’s child. The Form 4 was signed by an attorney-in-fact on 10/01/2025.

Positive

• Transactions disclosed explicitly and promptly via Form 4, including option grant, sales and 10b5-1 plan adoption
• Use of a pre-established Rule 10b5-1 trading plan (adopted 02/27/2025) to effect sales, which is documented in the filing

Negative

• Insider sold 50,000 shares on 10/01/2025 (8,245 at weighted average $98.9063 and 41,755 at weighted average $98.3797), reducing direct holdings
• Large gross proceeds from sales (implied by volumes and prices disclosed) represent a material disposition of insider-held shares on that date

Insights

Financial Analyst

TL;DR: Insider exercised options and sold 50,000 shares under a pre-established 10b5-1 plan; sale proceeds reflect prices near $98.4–$98.9.

The transactions combine an exercise/grant event (50,000-share option at $26.15) and contemporaneous market sales of 50,000 shares at weighted average prices of $98.9063 and $98.3797. The use of a 10b5-1 plan (adopted 02/27/2025) signals pre-planned disposition rather than opportunistic trading. From a capital-impact perspective, the option grant with multi-year vesting maintains alignment with long-term compensation structures while the sales materially reduced the reporting person’s direct holdings by the number of shares sold. These are routine, reportable insider transactions without additional corporate disclosures in this filing.

Corporate Governance Expert

TL;DR: Filing shows compliant Section 16 reporting: option grant details, Rule 10b5-1 execution, and explicit disclaimer of child-held shares.

The Form 4 provides clear compliance signals: it documents the grant terms (exercise price $26.15, vesting in four equal annual installments, expiration 12/01/2027), lists sales executed pursuant to a 10b5-1 plan adopted 02/27/2025, and includes an express disclaimer regarding 5,234 shares held by the reporting person’s child. The signature by an attorney-in-fact is included. These elements reflect standard governance and disclosure practices for insider equity transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Fitzgerald Joseph Michael

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Group Pres, Cardiology

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		M(1)		50,000	A	$26.15	228,342	D
Common Stock	10/01/2025		S(1)		8,245	D	$98.9063(2)	220,097	D
Common Stock	10/01/2025		S(1)		41,755	D	$98.3797(3)	178,342	D
Common Stock								5,234(4)	I	By Child

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$26.15	10/01/2025		M(1)			50,000	(5)	12/01/2027	Common Stock	50,000	$0.0000	50,000	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025.

2. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.86 to $98.96, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $97.86 to $98.85, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

4. The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.

5. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Boston Scientific (BSX) report on 10/01/2025?

The filing reports a 50,000-share option grant at an exercise price of $26.15 and sales of 8,245 and 41,755 shares on 10/01/2025.

Were the sales executed under a trading plan for BSX insider Joseph Fitzgerald?

Yes. The sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on 02/27/2025.

What were the weighted average sale prices reported for the shares sold?

The filing reports weighted average sale prices of $98.9063 for 8,245 shares and $98.3797 for 41,755 shares.

What are the exercise and expiration details of the option grant?

The option has an exercise price of $26.15, vests in four equal annual installments, and lists an expiration date of 12/01/2027.

Does the reporting person claim beneficial ownership of all listed shares?

The reporting person disclaims beneficial ownership of 5,234 shares held by his child.